8AP Stock Chart & Stats
€29.40
€1.80(5.66%)
At close: 4:00 PM EST
€29.40
€1.80(5.66%)
Day’s Range― - ―
52-Week Range€19.70 - €38.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.90B
Enterprise Value€1.29K
Total Cash (Recent Filing)€737.04M
Total Debt (Recent Filing)€35.74M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Jul 30, 2026EPS Estimate
-1.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.25
Shares Outstanding59,471,607
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€34.39Price Target Upside16.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.46
Revenue Forecast (FY)€104.72M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue GrowthSustained high gross margins (~88%) combined with positive TTM revenue growth indicate the company’s products scale efficiently. This supports long-term gross cash generation as sales expand, improving the odds that rising revenue can eventually cover fixed R&D and SG&A spend.
Commercial Launch ExecutionDemonstrated REMS implementation and early prescriber adoption show durable commercial capabilities. Effective specialty distribution and patient support reduce rollout risk, increasing probability that mitapivat and related launches can translate into a sustained, repeatable revenue base over coming quarters.
Conservative Balance Sheet & LiquidityA cash runway above $1 billion and minimal debt give flexibility to fund development and confirmatory trials without immediate refinancing. This structural liquidity shield reduces near-term solvency risk and allows management to prioritize strategic R&D and launch investments.
Bears Say
Persistent Cash BurnSustained multi-hundred-million dollar negative operating and free cash flow materially raises financing risk absent faster revenue scaling. Over months, continued burn can force dilution, debt raises, or spending cuts that reshape R&D timelines and commercial investment priorities.
Deep Operating Losses & Negative MarginsVery large operating losses indicate expenses far exceed current product revenue, limiting reinvestment capacity and depressing returns on equity. Until revenue materially outpaces fixed and variable costs, profitability and shareholder value creation remain structurally constrained.
Pipeline Setback: Tebapivat In SCDDeciding not to advance tebapivat in sickle cell disease reduces optionality and addressable near-term indications. This worsens pipeline risk and shifts growth reliance to fewer programs, increasing the business sensitivity to upcoming mitapivat regulatory and confirmatory outcomes.
Agios Pharma News
8AP FAQ
What was Agios Pharmaceuticals’s price range in the past 12 months?
Agios Pharmaceuticals lowest stock price was €19.70 and its highest was €38.80 in the past 12 months.
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is €1.90B.
When is Agios Pharmaceuticals’s upcoming earnings report date?
Agios Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 4 days.
How were Agios Pharmaceuticals’s earnings last quarter?
Agios Pharmaceuticals released its earnings results on Apr 29, 2026. The company reported -€1.484 earnings per share for the quarter, beating the consensus estimate of -€1.584 by €0.099.
Is Agios Pharmaceuticals overvalued?
According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued.
Does Agios Pharmaceuticals pay dividends?
Agios Pharmaceuticals does not currently pay dividends.
What is Agios Pharmaceuticals’s EPS estimate?
Agios Pharmaceuticals’s EPS estimate is -1.46.
How many shares outstanding does Agios Pharmaceuticals have?
Agios Pharmaceuticals has 59,471,607 shares outstanding.
What happened to Agios Pharmaceuticals’s price movement after its last earnings report?
Agios Pharmaceuticals reported an EPS of -€1.484 in its last earnings report, beating expectations of -€1.584. Following the earnings report the stock price went up 1.942%.
Which hedge fund is a major shareholder of Agios Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:8AP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€34.39 (16.99% Upside)
€34.39 (16.99% Upside)
Blogger Sentiment
Bullish
DE:8AP Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.82%
Trailing 12-Months
Company Description
Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
8AP Stock 12 Month Forecast
Average Price Target
€34.39
▲(16.99% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―